Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, ...

Zepbound is FDA-approved for weight loss in adults with obesity or overweight who have a weight-related condition. The side effects of semaglutide are quite similar to those of tirzepatide ...

The FDA has approved Wegovy to reduce heart attack ... the three doctors say they’re comfortable prescribing semaglutide long-term for weight loss for a patient eligible for the medication.

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7% ... as it was first approved in 2022, while semaglutide has been on the market since 2017.

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss ... The latest semaglutide (Ozempic; Novo Nordisk ...

The US Food and Drug Administration (FDA) has declared an end to the ... Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival ...